Skip to main content

Nobel Prize in Chemistry

Eric Betzig

Nobel week is a fascinating time of year. Each day brings an announcement of one of the prizes, in a way that starts with the hard sciences and seems to build toward the politically contentious pair -- Peace and Economics.

The news in the hard sciences is intriguing (and political in its own way surely, though I am happily abstracted from the sort of academic politics that would manifest itself in such matters). It is intriguing because the bestowal of an award on someone who certainly ISN'T a household name, like the chemists Eric Betzig, Stefan Hell, and William Moerner this year, forces various bright science journalists to explain their life work to the rest of us. And I always enjoy getting some easily digestible field about a subject to which I never otherwise give any thought at all.

Here is the prize committee's own explanation of the work of the three chemists who win this year.


I've put a photo of Eric Betzig at the top of this post -- due respect to the others named -- and so I'll include the official biography of Betzig.


This is all about nanotechnology, which may be the critical way forward for our species. Nina Porzucki, for PRI The World, explains nanotech and this Nobel's recognition of the field here:


Porzucki's essay includes a now-obligatory reference to a lecture delivered by Richard Feynman in 1959 that serves as sort of a manifesto for the field to this day. "There's Plenty of Room at the Bottom." Now I've referenced it, too. I told you it was obligatory.


And here is coverage of the subject from India:


Here's an explanation of why I think this field of science might just be THE issue in our day that will still matter, say, 1,000 years from now.



Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

England as a Raft?

In a lecture delivered in 1880, William James asked rhetorically, "Would England ... be the drifting raft she is now in European affairs if a Frederic the Great had inherited her throne instead of a Victoria, and if Messrs Bentham, Mill, Cobden, and Bright had all been born in Prussia?"

Beneath that, in a collection of such lectures later published under James' direction, was placed the footnote, "The reader will remember when this was written."

The suggestion of the bit about Bentham, Mill, etc. is that the utilitarians as a school helped render England ineffective as a European power, a drifting raft.

The footnote was added in 1897. So either James is suggesting that the baleful influence of Bentham, Mill etc wore off in the meantime or that he had over-estimated it.

Let's unpack this a bit.  What was happening in the period before 1880 that made England seem a drifting raft in European affairs, to a friendly though foreign observer (to the older brother…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…